XM no presta servicios a los residentes de Estados Unidos de América.
N
N

Novartis


Noticias

Foreign banks target Switzerland after UBS takeover of Credit Suisse

Foreign banks target Switzerland after UBS takeover of Credit Suisse By Oliver Hirt and Noele Illien ZURICH, June 24 (Reuters) - As Credit Suisse fades into history following its takeover by UBS last year, global banks are expanding in Switzerland to take advantage of companies' desire to spread their business. France's BNP Paribas BNPP.PA , Deutsche Bank DBKGn.DE and U.S.
B
C
D
N
N
U

Sarepta surges as investors cheer expanded use of gene therapy

UPDATE 2-Sarepta surges as investors cheer expanded use of gene therapy Adds background on FDA decision in paragraph 4, CEO quote in paragraphs 8 & 9, analyst quote in paragraph 12 & 13 By Mariam Sunny and Bhanvi Satija June 21 (Reuters) - Sarepta Therapeutics SRPT.O shares surged as much as 40% to a more than three-year high on Friday as an expanded use approval cemented its dominant position in the gene therapy market for Duchenne muscular dystrophy (DMD).
N
P
T

Morphosys And Novartis Sign Delisting Agreement

BRIEF-Morphosys And Novartis Sign Delisting Agreement June 20 (Reuters) - MORPHOSYS AG MORG.DE : MORPHOSYS AND NOVARTIS SIGN DELISTING AGREEMENT AND INTEND TO IMPLEMENT A MERGER SQUEEZE-OUT OF MORPHOSYS’ MINORITY SHAREHOLDERS MORPHOSYS AG - ACCEPTANCE PERIOD OF TAKEOVER OFFER AND STATUTORY TWO-WEEK ADDITIONAL ACCEPTANCE PERIOD ENDED ON MAY 13, 20
M
N

Novartis BidCo Germany plans merger squeeze-out of Morphosys minority shareholders

BRIEF-Novartis BidCo Germany plans merger squeeze-out of Morphosys minority shareholders June 20 (Reuters) - MORPHOSYS AG MORG.DE : NOVARTIS BIDCO GERMANY AG INTENDS TO IMPLEMENT A MERGER SQUEEZE-OUT OF MORPHOSYS AG’S MINORITY SHAREHOLDERS NOVARTIS BIDCO GERMANY AG CONFIRMED THAT IT CURRENTLY HOLDS APPROXIMATELY 91.04% OF TOTAL MORPHOSYS AG SHARE
M
N

EU regulator requires secondary cancer risk warning for T therapies

UPDATE 3-EU regulator requires secondary cancer risk warning for CAR-T therapies Changes headline, adds background in paragraphs 3, 5 & 6 June 14 (Reuters) - The European health regulator said on Friday cancer cell therapies known as CAR-T treatments must include a written warning of an associated risk for secondary blood cancers in patients who use them and that patients should be monitored for life.
G
N

EU regulator mandates label updates on T cancer therapies

EU regulator mandates label updates on CAR-T cancer therapies June 14 (Reuters) - The European health regulator said on Friday product information for a class of cancer therapies known as CAR-T treatments would be required to highlight risk of secondary cancers in patients who use them, ending a five-month safety review. Reporting by Mariam Sunny i
G
N

New Pharma will crowd out Big Pharma

BREAKINGVIEWS-New Pharma will crowd out Big Pharma The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Aimee Donnellan LONDON, June 11 (Reuters Breakingviews) - Big Pharma is under threat from tech-driven upstart rivals. The values of large, established players like $159 billion Pfizer PFE.N , $230 billion Novartis NOVN.S and $216 billion Roche ROG.S are converging with newer players like $121 billion Vertex Pharmaceuticals VRTX.O .
A
G
N
P
R
R
S
V

Swiss stocks - Factors to watch on June 10

Swiss stocks - Factors to watch on June 10 ZURICH/GDANSK, June 10(Reuters) - Here are some of the main factors that may affect Swiss stocks on Monday: COMPANY STATEMENTS * Roche ROG.S - European Commission approves Roche’s Alecensa * Barry Callebaut AG BARN.S - Places New EUR 700 Mln Denominated Bond * Dormakaba Holding AG DOKA.S - To Divest Its Sub-Saharan African Business * Metall Zug AG METN.S , METN.S - Announces Start of JV ANALYSTS' VIEWS BARRY CALLEBAUT AG BARN.S - BERENBERG RAISES TARG
N
N
R
S

Law firm defends work in $5.6 bln card fee case after disclosing fake claims

Law firm defends work in $5.6 bln card fee case after disclosing fake claims By Mike Scarcella June 7 (Reuters) - A law firm that earlier said it unknowingly submitted fake claims as part of a $5.6 billion settlement with Visa and MasterCard told a U.S. judge on Thursday that other parties had also submitted fraudulent material in the case. Responding to a request for more information from the Brooklyn judge overseeing the antitrust case, New York-founded Milberg Coleman Bryson Phillips Grossman
N
V

US judge orders probe of Novartis $30 mln settlement claims process

US judge orders probe of Novartis $30 mln settlement claims process By Brendan Pierson June 6 (Reuters) - A federal judge has ordered a probe of the claims distribution process in a $30 million settlement by Novartis NOVN.S with consumers and health plans in an antitrust class action over its hypertension drug Exforge, citing concerns about its integrity.
N

Staff at drugmaker under U.S. scrutiny worked with Chinese military scientists

INSIGHT-Staff at drugmaker under U.S. scrutiny worked with Chinese military scientists By Kirsty Needham, Andrew Silver SYDNEY/SHANGHAI, June 6 (Reuters) - Employees of drugmaker WuXi AppTec, under U.S. scrutiny for its links to the Chinese military, co-invented altitude sickness treatments with People's Liberation Army (PLA) scientists, according to public patent records and science papers reviewed by Reuters.
N

Novartis, Roche unit and others face Italy antitrust probe over eye drug

UPDATE 3-Novartis, Roche unit and others face Italy antitrust probe over eye drug Adds Biogen comment in last paragraph ROME, June 6 (Reuters) - Italy's antitrust regulator said on Thursday it had launched an investigation into pharmaceutical companies including Novartis NOVN.S and Roche-controlled ROG.S Genentech for having potentially restricted competition in the sale of an eye drug.
B
N
R

Novartis and others face Italy antitrust probe over eye drug

Novartis and others face Italy antitrust probe over eye drug ROME, June 6 (Reuters) - Italy's antitrust regulator said on Thursday it had launched a probe into several pharmaceutical companies, including Novartis NOVN.S , for having potentially restricted competition in the sale of a drug for eye conditions. Samsung Bioepis, Biogen, Genentech and Novartis, and some of their Italian, Dutch and UK units, allegedly coordinated their commercial strategies to delay the launch in Italy of Byooviz, a d
B
N
R

Cytokinetics rises; CEO confirms prior M&A interest in company

BUZZ-Cytokinetics rises; CEO confirms prior M&A interest in company ** Shares of drug developer Cytokinetics CYTK.O rise 9.5%to $53 ** CEO Robert Blum said at an industry conference that CYTK was engaged in strategic talks with potential partners for its experimental heart disease drug, aficamten, throughout 2023 ** CYTK was approached by one of the third parties with whom they had previously engaged with regarding acquisition of the company, Blum says ** Blum says CYTK's board was supportive of
N

Lawsuits pile up over state laws on discounts for hospitals' contract pharmacies

Lawsuits pile up over state laws on discounts for hospitals' contract pharmacies By Brendan Pierson June 3 (Reuters) - The pharmaceutical industry has filed at least four lawsuits this year challenging state laws requiring drugmakers to offer discounts on drugs dispensed by third-party pharmacies that contract with hospitals and clinics serving low-income populations.
N

Swiss stocks - Factors to watch on June 3

CORRECTED-Swiss stocks - Factors to watch on June 3 Removes rating changes with wrong date ZURICH/GDANSK, June 3 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Monday: UBS UBSG.S UBS on Friday completed the merger of the main parent companies of the Swiss bank and Credit Suisse, which it acquired last year after its longtime rival collapsed, putting an end to one of the bastions of the country's financial sector.
G
N
R
S
U
S
T

Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes

Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes June 2 (Reuters) - Treatment with Bristol Myers Squibb's BMY.N immunotherapies Opdivo and Yervoy prior to surgery for patients whose skin cancer had spread to lymph nodes had better outcomes than those who did not get the drugs before node removal procedures, according to data from a late-stage trial released on Sunday.
N

Novartis says phase III trial shows Kisqali product reduces risk of cancer recurrence for early breast cancer patients with high-risk node-negative disease

BRIEF-Novartis says phase III trial shows Kisqali product reduces risk of cancer recurrence for early breast cancer patients with high-risk node-negative disease May 31 (Reuters) - NOVARTIS AG NOVN.S : LATEST ANALYSIS OF NOVARTIS NATALEE STUDY SHOWS KISQALI® REDUCES RISK OF CANCER RECURRENCE FOR EARLY BREAST CANCER PATIENTS WITH HIGH-RISK NODE-NEG
N

Novartis Scemblix Phase III Data Shows Superior Efficacy With Favorable Safety & Tolerability Profile In Adults With Newly Diagnosed Cml

BRIEF-Novartis Scemblix Phase III Data Shows Superior Efficacy With Favorable Safety & Tolerability Profile In Adults With Newly Diagnosed Cml May 31 (Reuters) - Novartis AG NOVN.S : NOVARTIS SCEMBLIX PHASE III DATA SHOWS SUPERIOR EFFICACY WITH FAVORABLE SAFETY & TOLERABILITY PROFILE IN ADULTS WITH NEWLY DIAGNOSED CML NOVARTIS: SCEMBLIX (ASCIMINIB)
N

Novartis leukemia drug more effective than older treatments in trial

Novartis leukemia drug more effective than older treatments in trial By Christy Santhosh May 31 (Reuters) - Swiss drugmaker Novartis NOVN.S said patients with a type of leukemia who took its Scemblix had a significantly better response and a lower dropout rate than those who received current standard-of-care drugs in a late-stage study with details presented on Friday.
N
P



Condiciones

Activos populares

Descargo de responsabilidades: Cada una de las entidades de XM Group proporciona un servicio de solo ejecución y acceso a nuestra plataforma de trading online, permitiendo a una persona ver o usar el contenido disponible en o a través del sitio web, sin intención de cambiarlo ni ampliarlo. Dicho acceso y uso están sujetos en todo momento a: (i) Términos y Condiciones; (ii) Advertencias de riesgo; y (iii) Descargo completo de responsabilidades. Por lo tanto, dicho contenido se proporciona exclusivamente como información general. En particular, por favor tenga en cuenta que, los contenidos de nuestra plataforma de trading online no son ni solicitud ni una oferta para entrar a realizar transacciones en los mercados financieros. Operar en cualquier mercado financiero implica un nivel de riesgo significativo para su capital.

Todo el material publicado en nuestra plataforma de trading online tiene únicamente fines educativos/informativos y no contiene –y no debe considerarse que contenga– asesoramiento ni recomendaciones financieras, tributarias o de inversión, ni un registro de nuestros precios de trading, ni una oferta ni solicitud de transacción con instrumentos financieros ni promociones financieras no solicitadas.

Cualquier contenido de terceros, así como el contenido preparado por XM, como por ejemplo opiniones, noticias, investigaciones, análisis, precios, otras informaciones o enlaces a sitios de terceros que figuran en este sitio web se proporcionan “tal cual”, como comentarios generales del mercado y no constituyen un asesoramiento en materia de inversión. En la medida en que cualquier contenido se interprete como investigación de inversión, usted debe tener en cuenta y aceptar que dicho contenido no fue concebido ni elaborado de acuerdo con los requisitos legales diseñados para promover la independencia en materia de investigación de inversiones y, por tanto, se considera como una comunicación comercial en virtud de las leyes y regulaciones pertinentes. Por favor, asegúrese de haber leído y comprendido nuestro Aviso sobre investigación de inversión no independiente y advertencia de riesgo en relación con la información anterior, al que se puede acceder aquí.

Advertencia de riesgo: Su capital está en riesgo. Los productos apalancados pueden no ser adecuados para todos. Por favor, tenga en cuenta nuestra Declaración de riesgos.